Although the incidence of tardive dyskinesia is expected to decline with increasing use of atypical antipsychotic drugs, the risk in susceptible patients, the continued use of older conventional antipsychotics, and the legacy of thousands of patients who previously acquired dyskinesias, underscore the relevance of this potentially irreversible adverse drug reaction. Considerable evidence has accumulated concerning the epidemiology, clinical presentation, pathogenesis and management of tardive dyskinesia. Better understanding of the condition is important not only for clinical practice, but also in elucidating the interaction between antipsychotic drugs and dyskinetic vulnerability associated with schizophrenia and ageing.
Introduction
Tardive dyskinesia (TD) is an involuntary movement disorder associated with antipsychotic drugs. Although variable in severity and persistence, it can be socially disfiguring and severe enough to compromise eating, speaking, or walking. Nevertheless, in spite of the promise of atypical antipsychotics, TD remains important to clinicians and researchers for several reasons. First, susceptible patients receiving atypical antipsychotics still carry some risk of developing the condition. Secondly, older conventional antipsychotics remain in widespread use throughout the world. Thirdly, there are thousands of patients with TD acquired during previous treatment with conventional antipsychotics. Fourthly, its pathogenesis remains unexplained. Finally, investigations of the synergy between drug effects and the susceptibility to spontaneous dyskinesias (SDs) may shed light on the pathogenesis of schizophrenia and other psychotic disorders.
History of dyskinesias in psychiatric disorders
Within a few years of the introduction of antipsychotic drugs, TD was widely recognized as an adverse drug reaction 1 . However, abnormal motor behaviour was described in psychotic patients for centuries before the use of antipsychotic drugs [1] [2] [3] [4] [5] [6] . In fact, movement disorders were considered an integral part of the biology of schizophrenia, and played a critical role in the classification of psychotic disorders 5, 6 . After antipsychotic drugs were developed, it became increasingly difficult to distinguish the motor adverse effects of drugs from the underlying disease process. But recent studies of drug-naïve first-episode patients, and of untreated schizophrenic patients drawn from historical records or living in developing nations, have examined the frequency of disease-associated SDs apart from drug effects.
In these studies, the prevalence of SD among patients with chronic schizophrenia varied between 0 and 53% depending on variables such as age and diagnostic cri-teria2.3. Fenton reported that the rate in schizophrenic patients was approximately 4% in first-episode patients, rising with age and chronicity to 40% for patients aged 60 years or older 7 . The risk was correlated with cognitive dysfunction, negative symptoms, and a poor-prognosis-deficit syndrome, perhaps serving as a marker for a severe subtype of schizophrenia 7, 8 .
In elderly populations, the prevalence of SD ranges from 0 to 36% 9 . The rate is low among the normal elderly, but increases significantly in association with institutionalization, poor dentition, and comorbid medical and neurological disorders 9 .
Considering the overlap between susceptibility to SD and TD, several investigators estimated the corrected prevalence of drug-induced dyskinesias by subtracting the rate of SD from the rate of TD [9] [10] [11] . The results demonstrate that the true prevalence of TD, above the background rate of disease-related SD, is approximately 10-20% [9] [10] [11] .
The occurrence of SD implies that it may be artificial to separate drug effects from underlying disease processes in the production of dyskinesias 5 . As suggested by Casey, "treatment with typical neuroleptics converts a covert vulnerability to develop SD that may eventually become clinically present to an overt expression of drug-provoked TD that develops sooner and in more patients" 4 .
Epidemiology

Methods
Numerous studies on the frequency of TD have yielded very different estimates, reflecting methodological difficulties in obtaining reliable data 3 . For instance, results depend on the sensitivity and specificity of assessment techniques and diagnostic criteria. Also, the risk varies depending on the susceptibility of the population sampled for study. TD is not necessarily consistent or persistent in all cases. Its severity fluctuates over time and is affected by the state of anxiety, activation, or arousal in a given patient at a specific time. Its prevalence in a population also reflects a dynamic process, some cases improving or remitting while other new cases emerge.
Finally, the incidence of TD is affected by drug treatment. Increasing doses or potency of antipsychotic drugs may suppress it, whereas reduced dosages or potency, poor compliance, and use of antiparkinsonian drugs or stimulants may unmask or worsen it. The importance of the masking effect of antipsychotics, resulting in false-negative cases, was demonstrated by Woerner et al. 12 , who found emergent dyskinesias in 34% of patients withdrawn from medications. However, withdrawal dyskinesias frequently resolve and may be unrelated to persistent TD 3 .
Prevalence and incidence
Estimates of the prevalence of TD with conventional antipsychotics range from 3 to 62% with a mean of 24% 3, 13 . Several studies have shown a cumulative incidence of about 5% annually, reaching 20-25% at the end of 5 or 6 years 3 . In studies of first-episode patients with limited prior drug exposure, the cumulative incidence was 6-12% in the first year, reaching 15% after 4 years, even when low doses of antipsychotics were used 14, 15 .
The risk and incidence in elderly patients is significantly higher 3, 16, 17 . The cumulative annual incidence found in patients over the age of 45 was 25-30% after one year of treatment with antipsychotics, rising to 50-60% after 3 years of treatment 16, 17 .
Atypical antipsychotics
The atypical antipsychotics are less likely to impair extrapyramidal function and cause TD 4, 16, 18, 19 . There are no convincing data implicating clozapine as a cause 3, 18 . Although a few possible cases have been reported with clozapine, the effect of prior treatment with other antipsychotics could not be excluded. Apart from isolated case reports, data from long-term trials suggest that the annual risk of TD with risperidone is about 1%, or one-sixth the risk with haloperidol 18 . Jeste et al. 20 reported an annual risk of 2.6% in elderly patients, one-tenth the risk found with haloperidol. Similarly, the risk with olanzapine is about one-twelfth the risk with haloperidol 18 . Beasley et al. 21 found a 1-year risk of 0.52% with olanzapine, and essentially no new cases of TD occurred beyond the initial period of treatment when dyskinesias emerged following withdrawal of previous antipsychotics. Preliminary data suggest a similar low incidence with quetiapine, ziprasidone, and aripiprazole, although long-term safety studies with these agents are few. Dolder and Jeste 22 showed that, in older patients with borderline TD at baseline, atypical antipsychotics as a class were associated with half the risk for developing definitive TD compared with conventional agents.
In conclusion, there is substantial evidence that the risk of TD is dramatically less with atypical antipsychotics. Although older conventional antipsychotics increased the risk of dyskinesias by 15-20% over the risk of SD occurring in untreated patients, the minimal risk with atypical agents is indistinguishable from and perhaps even lower than the risk of SD. Thus atypicals may either not cause dyskinesias at all, or may even reduce the risk of SD developing.
Risk factors
Identification of reliable risk factors could be helpful in formulating treatment strategies to prevent TD 3 . Although numerous risk factors have been proposed, validity has been difficult to establish because of confounding interactive effects. Age has been the most consistently replicated risk factor for both TD and SD 3, 15, 17 . Female sex and race have been proposed in some studies 3, 16 . Schizophrenic patients with prominent negative or cognitive symptoms and poor treatment response may be at increased risk 3, 14, 15 . Patients with mood disorders may also be at risk 23 . Finally, elderly patients with medical or neurological conditions have heightened risk 3, 9 and diabetes in particular may increase the incidence 3 .
It has been difficult to correlate risk with drug potency, dose, or even blood concentration 3 . Although a positive correlation seems intuitive and has been found in some studies 3, 14, 15 several variables obscure confirmatory results, including differences in pharmacokinetics between individuals, polypharmacy, noncompliance, and differences in susceptibility among patients regardless of drug dosage. Administration of anticholinergic drugs acutely worsens existing TD, and has also been implicated in increasing the incidence 3, 24, 25 . However, the risk of developing TD associated with anticholinergics may be partly mediated by acute extrapyramidal reactions for which they are prescribed, and which may independently increase the risk 24 .
Clinical features
TD is a polymorphous involuntary movement disorder. In its most common form it is characterized by involuntary, repetitive, purposeless hyperkinetic movements 1, 3 . It most often affects the orofacial muscula-ture with chewing, tongue protrusion, lip smacking, puckering, and pursing, or eye blinking and blepharospasm 1 . Choreoathetoid movements of the hands, and feet are also common. Axial symptoms affecting the neck, shoulders, spine, or pelvis may be observed. Occasionally, dyskinesias can affect breathing, swallowing, or speech.
Characteristically in TD, as with most involuntary movement disorders, dyskinesias increase with emotional arousal, activation, or distraction, and diminish with relaxation, sleep, or voluntary effort 3 . As a result, the symptoms fluctuate over time, so that repeated measurements are necessary for a reliable assessment of severity 3, 26 .
TD may present with movements other than the classic and common choreoathetoid symptoms. These may coexist with classic symptoms, but may represent separate subtypes. For example, tardive dystonia may be more severe, persistent, and disabling than TD, and may respond to anticholinergic agents 2, 3 . Akathisia and other movement disorders may also occur as tardive variants 2,3 . Although different diagnostic schemes have been proposed, the criteria proposed by Schooler and Kane 26 have been widely accepted. These authors required at least 3 months of exposure to antipsychotics; ratings of at least moderate severity in one or more body areas, or ratings of at least mild severity in two or more body areas; and the absence of other conditions that might cause dyskinesias. To confirm the presence of persistent TD, the criteria must be fulfilled over a 3-month period.
Ratings of severity used in diagnostic criteria are obtained in a structured examination using the abnormal involuntary movement scale (AIMS), which is the most widely used of several clinical rating scales available for measuring dyskinesias 27 . Other techniques to objectify measurements include instrumentation and frequency counts 3 .
Differential diagnosis
Not all dyskinesias can be attributed to antipsychotics. A careful neurological evaluation is indicated for all patients with new-onset dyskinesias. Other disorders to consider in the differential diagnosis of TD include acute extrapyramidal reactions to antipsychotic drugs, transient withdrawal dyskinesias, and peculiarities of movement associated with schizophrenia. Neurological disorders that can produce similar dyskinesias include Wilson's disease, Huntington's disease, Sydenham's chorea, chorea gravidarum, Fahr's syndrome, systemic lupus, senile chorea, Meige's syndrome, edentulous chorea, infarction or lesions of the basal ganglia, Tourette's syndrome, torsion dystonia, spasmodic torticollis, hyperthyroidism, hypoparathyroidism, and conversion disorder 3 .
Several drugs besides antipsychotics are associated with movement disorders, including caffeine, phenytoin, estrogens, levodopa, antidepressants, antihistamines, and stimulants 3 .
Pathogenesis
In spite of extensive research into the pathophysiology underlying TD, no single mechanism has been confirmed. Any viable hypothesis has to take into account not only the characteristics and course of the condition, but also its reduced incidence with atypical drugs, and the correlations between TD and SD associated with schizophrenia or advancing age.
Several leading hypotheses have been investigated 28 . The dopamine-receptorhypersensitivity hypothesis proposes that TD results from increased sensitivity to dopamine of nigrostriatal-system dopamine receptors as a consequence of chronic antipsychotic-induced dopamine-receptor blockade. This model is consistent with the pharmacological effects of antipsychotics on dopamine receptors, and the worsening of dyskinesias in response to dopamine agonists. However, only limited or negative evidence for this hypothesis has emerged from studies with antipsychotics in rodents or nonhuman primates 28 . None of these animal models reproduces the late onset, individual variability, and potentially irreversible course of TD. In humans, post-mortem studies of brain receptors and studies of dopamine metabolites in the cerebrospinal fluid failed to support this hypothesis, leading to a consensus that dopamine may play a secondary or modulatory role 28 .
Another hypothesis suggests γ-aminobutyric acid (GABA) insufficiency as the underlying mechanism. Other neurochemical hypotheses have been proposed implicating noradrenaline, serotonin, iron, oestrogen, and amino acid or glucose metabolism 28 .
An alternative approach presupposes that TD reflects structural damage resulting from neurotoxicity of antipsychotics. Increased catecholamine metabolism resulting from antipsychotic-induced dopamine-receptor blockade produces free radicals which may cause irreversible cellular injury. Studies in rodents have shown evidence of cell loss or alterations of postsynaptic densities in the caudate nucleus associated with conventional antipsychotics 28 . Neuroimaging studies in patients have not shown consistent changes in ventricular brain ratios. However, recent studies have shown larger caudate regions in patients receiving conventional antipsychotics, but not with clozapine 28 .
A similar structural hypothesis articulated by Miller and Chouinard 29 proposes that TD is associated with damage to striatal cholinergic neurons as a consequence of overactivity due to the loss of dopamine-mediated inhibition. Selective histological damage to these cells in the brain has been found post mortem after chronic administration of antipsychotic drugs in rats and in patients with TD.
These proposed etiological mechanisms have underpinned specific pharmacological treatment strategies for TD, as discussed below.
Treatment
There is no uniformly effective treatment for TD 30, 31 . The best approach is to prevent it by using conservative doses of antipsychotics and selecting atypical agents. Suggested management of TD is as follows: (1) prevent TD using low doses and atypical antipsychotics; (2) inform patients of TD risk and assess them routinely; (3) if dyskinesias emerge, consider differential diagnosis; and (4) treatment. Regarding treatment, (1) withdrawing antipsychotics enhances recovery but risks psychosis; (2) conventional antipsychotics suppress TD but inhibit recovery; (3) atypical antipsychotics suppress TD and may enhance recovery; (4) taper anticholinergic drugs if possible; (5) benzodiazepines and vitamin E may help; and (6) cholinesterase inhibitors. Routine assessment for emerging TD and informing patients of the risk are also essential for good practice and to avoid medicolegal liability.
In analysing the efficacy of specific agents in treating the established condition, it is important to distinguish several terms and consider the natural course of the disorder. Masking or suppression by a drug is different from reversal or recovery from TD. Furthermore, a drug may actively reverse the pathophysiology underlying TD, or may act passively, simply allowing it to resolve naturally. Although about 50% of patients with TD show no change and about 10-30% show worsening, studies have shown that even with continued treatment with conventional antipsychotics, TD remits in 14-36% of cases 18, 30, 31 . Most patients have a fluctuating course.
Reversible withdrawal dyskinesias are distinct from persistent, irreversible TD 26 . In patients from whom antipsychotics have been withdrawn, initial worsening in over 50% may be followed by long-term improvement in 20-36% of patients, although complete remission is rare 30, 31 . However, the high risk of psychotic relapse in most patients precludes drug withdrawal as a practical treatment.
Therefore, the first treatment option is switching to atypical antipsychotics. In short-term studies, most atypical antipsychotics acutely reduce dyskinesia ratings 18 . These findings indicate that even with lower dopamine receptor affinities, atypical antipsychotics resemble more potent drugs, like haloperidol, which mask or suppress TD in about 67% of patients 30, 31 .
A few published long-term studies support a beneficial effect of atypical drugs on the course of TD. Treatment with clozapine has resulted in 50% improvement in many patients, and remission in up to 34% of patients 18 . In some studies, remission was maintained even after clozapine was withdrawn. Similarly, studies with olanzapine have shown improvement of up to 70% in dyskinesia ratings among patients with TD, which endured even after significant reductions in olanzapine dosages 18 . These studies with clozapine and olanzapine, in which the expected rebound worsening in TD after drug withdrawal did not occur, suggest a potential ameliorative rather than a simple suppressive effect on TD. Clozapine has also been reported to be effective in tardive dystonia 3 .
Dopamine-depleting agents have reduced TD and tardive dystonia in some patients 30, 31 . Dopamine agonists have been tried experimentally to reverse long-term effects of antipsychotics on dopamine receptors but without success. Noradrenergic antagonists and agonists have been used with limited success in small studies. Benzodiazepines have shown promise in reducing TD in about 50% of patients, whereas valproate, baclofen, and other GABAergic drugs are less effective. Other agents that have been tried with variable results include lithium, calcium-channel antagonists, serotonergic drugs, vitamins, branched-chain amino acids, neuropeptides, electroconvulsive therapy, and botulinum toxin (for dystonia).
In view of the structural hypothesis of damage from free radical formation, vitamin E. It showed promise in initial studies as an effective antioxidant in treating existing TD 30, 31 . However, a large prospective study failed to support this effect 32 . Nevertheless, vitamin E and other antioxidants, or lithium and other compounds may still hold promise in preventing TD from developing.
Finally, agents affecting cholinergic function have been investigated 25, 30, 31 . Anticholinergic drugs worsen TD, which may actually improve in 60% of patients after these drugs are discontinued 30 . In contrast, cholinergic drugs may have selective benefits in patients with tardive dystonia. To counterbalance presumed dopamine hyperactivity in TD, several acetylcholine precursors were investigated with disappointing results 30, 31 . However, we hypothesized that if striatal cholinergic neurons are damaged, they may be unable to utilize precursors. To bypass this obstacle, we and others proposed using cholinesterase inhibitors to increase synaptic acetylcholine, and have obtained promising initial results in patients with TD 25, 30 .
Conclusion
Although the incidence of new cases of TD may decline with the use of atypical antipsychotics, the legacy of thousands of existing cases and the continued use of conventional agents underscore the enduring clinical importance of this disorder. Rational guidelines for its prevention and treatment can be derived from extensive research evidence. In addition, TD raises intriguing and unanswered questions concerning the pathophysiological consequences of long-term antipsychotic administration, and the relationship between drug effects and dyskinesias associated with schizophrenia and ageing.
